Immunovant (IMVT) CLO mandated share sale to cover RSU tax withholding

Rhea-AI Filing Summary

Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported an open-market sale of 2,634 shares of common stock at $35.39 per share. This transaction was executed to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units.

According to the disclosure, the sale was mandated by the company’s "sell to cover" election and was not a discretionary trade by the officer. Following the transaction, Van Tuyl directly holds 180,597 shares of Immunovant common stock.

Insider Trade Summary

Net Seller: 2,634 shares ($93,217)

Net Sell 1 txn

Insider Van Tuyl Christopher

Role Chief Legal Officer

Sold 2,634 shs ($93K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,634	$35.39	$93K

Holdings After Transaction: Common Stock — 180,597 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 2,634 shares Sale price: $35.39 per share Shares held after transaction: 180,597 shares +2 more

5 metrics

Shares sold 2,634 shares Open-market sale on June 18, 2026 to cover taxes

Sale price $35.39 per share Price for the 2,634 common shares sold

Shares held after transaction 180,597 shares Direct holdings following the reported sale

RSUs granted 109,956 RSUs Restricted stock units granted on December 16, 2024

RSUs vested 6,872 RSUs Portion of grant that vested on June 16, 2026

Key Terms

restricted stock units ("RSUs"), sell to cover, tax withholding obligations, open-market sale

4 terms

restricted stock units ("RSUs") financial

"the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

sell to cover financial

"funded by a "sell to cover" transaction and does not represent a discretionary transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Tuyl Christopher

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		S		2,634(1)	D	$35.39	180,597	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on June 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Immunovant (IMVT) disclose for Christopher Van Tuyl?

Immunovant disclosed that Chief Legal Officer Christopher Van Tuyl sold 2,634 shares of common stock at $35.39 per share. The sale was linked to tax withholding on recently vested restricted stock units rather than a discretionary open-market trade.

Why did Immunovant (IMVT) Chief Legal Officer sell 2,634 shares?

The 2,634 shares were sold to satisfy tax withholding obligations from vesting and settlement of restricted stock units. Immunovant required a mandated "sell to cover" transaction, meaning the sale was automatic and not an elective decision by the executive.

How many Immunovant (IMVT) shares does Christopher Van Tuyl hold after this Form 4?

After the reported transaction, Christopher Van Tuyl directly holds 180,597 shares of Immunovant common stock. This reflects his position following the 2,634-share sale used to cover tax withholding on vested restricted stock units granted earlier.

What equity awards are referenced in this Immunovant (IMVT) Form 4 filing?

The filing references a grant of 109,956 restricted stock units awarded on December 16, 2024. Of this grant, 6,872 RSUs vested on June 16, 2026, triggering tax obligations that led to the mandatory sell-to-cover share sale.

Was the Immunovant (IMVT) insider sale by the CLO a discretionary trade?

No, the sale was not discretionary. The company elected to cover tax withholding obligations for vested restricted stock units through a required "sell to cover" transaction, so the Chief Legal Officer did not independently choose the timing or size of this sale.